000 02448cam a2200325 a 4500
003 EG-GiCUC
008 160517s2015 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.23.Ph.D.2015.Ah.C
100 0 _aAhmad Mahrous Dewidar
245 1 0 _aCarboplatin/gemcitabine as first line treatment of metastatic triple negative breast cancer /
_cAhmad Mahrous Dewidar ; Supervised Mohammad Ahmad Hassan , Mohammad Sayed Abdelkader , Wael Samir Makar
246 1 5 _aعلاج سرطان الثدي السلبي الثلاثي المنتشر باستخدام عقاري الجيمسيتابين/كاربوبلاتين كخط علاج أول
260 _aCairo :
_bAhmad Mahrous Dewidar ,
_c2015
300 _a72 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (clinical)
520 _aBackground and objectives: Triple-negative breast cancer is regarded as an aggressive disease for which effective targeted therapy is not yet available. Results: Among the 34 included patients , 33 were considered valuable for response as one patient refused to continue treatment after she received the first week of treatment due to grade 3 vomiting, four patients (12.1%) achieved complete response and 20 patients (60.6%) had a partial response giving an overall response rate of 72.7% (95% CI, 60%-84%), one patients(3%) had stable disease > 6 months giving clinical benefit rate(CBR) of 75.7% (25/٣٣). The median duration of response of 6.5 months. while 8 cases progressed in treatment (24.7%), Median progression-free survival, was 6.18 months (95% CI 5.61{u2013}7·30 ) .Overall survival was 12.7month (range2-24, SD: 5.1) . Neutropenia G3 in 3 patients(9%) one of them developed febrile neutropenia ,anemia grade three in 4\33 patients(12%), thrombocytopenia grade 3 in 5 patinets (15%). Conclusions:. This study suggested that The combination was efficacious and well tolerated  
530 _aIssued also as CD
653 4 _aBreast cancer
653 4 _aMetastatic
653 4 _aTriple negative
700 0 _aMohammad Ahmad Hassan ,
_eSupervisor
700 0 _aMohammad Sayed Abdelkader ,
_eSupervisor
700 0 _aWael Samir Makar ,
_eSupervisor
905 _aNazla
_eRevisor
905 _aSoheir
_eCataloger
942 _2ddc
_cTH
999 _c56504
_d56504